Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Comms

- PMLiVE

GSK’s RSV vaccine Arexvy approved by FDA for use in adults aged 50 to 59 years

The decision comes just over a year after the FDA approved Arexvy for use in adults aged 60 years and older

- PMLiVE

GSK enhances oligonucleotide capabilities with $50m Elsie acquisition

The ability of oligonucleotides to modulate gene expression makes them an attractive modality for drugmakers

- PMLiVE

Stemming the Flow–Medscape Presents at HLTH Europe

Medscape Education will be attending HLTH Europe from June 17-20. Be sure to drop by our booth to participate in our survey and enjoy exciting giveaways. Additionally, Dr. John Whyte,...

Medscape Education Global

- PMLiVE

Takeda’s enzyme replacement therapy recommended by CHMP for rare blood clotting disorder cTTP

If approved, rADAMTS13 will be the first and only enzyme replacement therapy in the EU indicated for cTTP

- PMLiVE

De-mystifying the NHS – What you need to know about the NHS as a market for your health technology

Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a...

Mtech Access

- PMLiVE

How to hack a problem like healthcare

To create the most compelling clinical and cost-benefit arguments, the quickest and most comprehensive answers come by ‘bringing the outside in’ and treating the problem as a ‘hack’.

EatMoreFruit

- PMLiVE

Disconnected pharma: Navigating digital challenges and priorities in 2024

We are delighted to present Graphite’s research whitepaper for 2024 — and this year we are able to share the challenges and priorities that digital leaders are finding, in this...

Graphite Digital

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

- PMLiVE

Takeda and Degron enter molecular glue degrader partnership worth over $1.2bn

The companies will focus on targets in oncology, neuroscience and inflammation

- PMLiVE

GSK’s long-acting biologic shown to reduce severe asthma attacks in phase 3 studies

Approximately 200,000 people in the UK have severe cases of the lung condition

- PMLiVE

GSK becomes first founding partner of global initiative tackling antimicrobial resistance

AMR could cause an estimated ten million deaths every year by 2050 unless action is taken

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links